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were evaluated.
Results: The site of aneurysm was splenic artery in
16 patients and common hepatic artery in 3 patients,
while the remaining two patients had gastroduodenal
and celiac aneurysms, respectively. All the lesions were
asymptomatic and the mean diameter was 23.9 mm.
Interventions consisted in coil embolization in 14 cases;
in four patients a covered stent was placed, while the
remaining three patients had a multilayer stent. Technical
success was 91%. There were no perioperative deaths; one
patient with splenic artery aneurysm had coils migration
with symptomatic splenic infarction and underwent
successful redo embolization. Median duration of
follow-up was 20 months. During follow-up one aneu-
rysm-unrelated death occurred. Neither thrombosis of
the treated artery nor reintervention were recorded.
Mean aneurismal diameter at the latest follow-up was
20.2 mm (P ¼ .001 in comparison with preoperative
values; 95% CI, 1.7-5.5). Complete exclusion of the aneu-
rysm occurred in all but one patient, who had a limited
increasing in the diameter of its splenic aneurismal sac
after coil embolization. Another patient developed
a more distal aneurysm of the splenic artery after 24
months. Freedom from aneurysm-related complications
at 2 years was 70% (SE 0.10).
Conclusions: In our experience, endovascular treat-
ment of visceral artery aneurysm is feasible with low perio-
perative morbidity. Follow-up results are satisfactory;
however the risk of developing aneurysm-related complica-
tions warrants the need for prolonged surveillance.
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Objectives: To compare renal function outcomes of
open repair, endovascular therapy and surveillance for renal
artery aneurysm (RAA).
Methods: Medical records of 40 patients with RAA
encountered between 2000 and 2012 were reviewed and
divided into 3 groups: endovascular therapy (ET, n ¼ 9),
open repair (OR; n ¼ 20), and surveillance (SV, n ¼ 11).
Creatinine level GFR estimates were based onMDRD equa-
tion. Nuclear studies were used to assess renal ﬂow/lateral-
ization. Hypertension (HTN) severity was assessed based
upon the number of medications used. SPSS package
(IBM) was used for statistical analysis.
Results: Demographics of all groups were similar. The
average size [mm] of RAA at the time of treatment was 19
6 6 for ET and 22 6 7.4 for OR. The average HTN meds
number before and after treatment for ET was 2.3 6 1.5
/ 3 6 1.8 and for OR: 1.7 6 1.1 / 1.7 6 0.9. HTNcontrol after intervention worsened in 33% of ET and
15% of OR patients and improved in 11.1% of ET and
20% of OR patients. The renal ﬂow was more frequently
lateralized (affected side ﬂow <45%) in the ET after the
procedure (20% (4/5) vs 50% (4/8) in OR). The average
GFR [mL/min/1.73m2] changed from 71.3 to 55.2 for
ET and from 82 to 81.4 for OR. No patient progressed
to dialysis during 1-10 years of surveillance. We also
observed signiﬁcant (P < .01) difference in hospital stay
(ET: 2.37 6 2.32 vs OR: 8.94 6 4.96 days). In the SV
group the average RAA size at presentation was 18 6
6.6 mm with no signiﬁcant growth over 2 to 66 months
of surveillance. The average GFR was 75.0 at presentation
and 79.7 at the latest visit. HTN control was similar with
2.4 6 1.9 meds at the beginning and 2.1 6 1.2 meds at
the latest visit. None of the SV patients crossed over to
treatment groups. RAA rupture was not observed.
Conclusions: Open repair of RAA tends to provides
better preservation of renal function than endovascular
treatment. While endovascular repair has less early
morbidity and shorter hospital stays, the reduced renal
preservation may have a negative impact on HTN control.
Author Disclosures: W. D. Jordan: WL Gore; Med-
tronic; Abbott, Consulting fees or other remuneration
(payment) Aptus; Volcano, Consulting fees or other remu-
neration (payment)WL Gore, Research GrantsMedtronic,
Research GrantsAbbott, Research GrantsAptus, Research
GrantsVolcano, Research GrantsMaquet, Research Grant-
sTerumo, Research GrantsEndologix, Research GrantsTri-
vascular, Research GrantsCook, Research Grantsev3,
Research GrantsLeMaitre, Research GrantsLombard,
Research Grants; T. C. Matthews: Nothing to disclose;
Z. Novak: Nothing to disclose; M. A. Passman: Nothing
to disclose; M. A. Patterson: Nothing to disclose.C6f: Poster Session-Practice Management; Other
PS92.
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Objectives: This study evaluated the utilization of
preoperative statins and their impact on perioperative
outcomes in patients undergoing open (OAR) or endovas-
cular (EVAR) aortic repair.
Methods: Patients $50 years of age with non-
ruptured AAA repair were identiﬁed in MedPAR ﬁles
2007-2008 utilizing ICD-9-CM codes. Preoperative sta-
tins use was identiﬁed using National Drug Codes in Part
D. c2 test, multivariable logistic regression, Kaplan-Meier
and Cox regression modeling was performed.
Results: 19,323 patients were identiﬁed undergoing
AAA repair (14,602 EVAR and 4721 OAR). 9,913
(50.3%) used statins before surgery. Bivariate analysis
demonstrated lower rates of hospital, 30-, 90-day and
1-year mortality in patients with statins compared to those
